Table 4.

Changes in HbA1c and GNRI to the effect of additional glucose‐lowering drug treatment

	HbA1c (%)			GNRI
	Baseline	12 months	P‐value	Baseline	12 months	P‐value
All patients
Normal	10.0 ± 2.4	7.3 ± 1.1	<0.001	106.6 ± 9.9	106.8 ± 9.8	0.699
Sarcopenia	10.3 ± 2.5	7.5 ± 1.1	<0.001	96.7 ± 10.9	99.7 ± 8.2	0.007
Male
Normal	10.1 ± 2.6	7.2 ± 1.1	<0.001	105.6 ± 9.3	106.2 ± 9.3	0.349
Sarcopenia	11.0 ± 2.9	7.6 ± 1.3	<0.001	95.5 ± 11.0	99.1 ± 8.1	0.019
Female
Normal	9.7 ± 2.0	7.3 ± 1.0	<0.001	107.8 ± 10.2	107.8 ± 10.5	0.888
Sarcopenia	9.6 ± 1.8	7.3 ± 0.8	<0.001	98.1 ± 10.9	100.6 ± 8.3	0.069

GNRI, geriatric nutritional risk index; HbA1c, glycated hemoglobin.